In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MGI Pharma gets exclusive rights to SuperGen's Dacogen

Executive Summary

The same day it reported it was expanding its cancer franchise by buying Zycos for $50mm and Aesgen for $32mm, MGI Pharma also announced a licensing deal with SuperGen. MGI now has exclusive worldwide development, marketing, and distribution rights to Dacogen (decitabine), a methylase inhibitor for patients with myelodysplastic syndromes (MDS, cancer of the bone marrow).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register